Clinical Trials Browser

Mesothelioma, Malignant × anetumab ravtansine × 1 year × Clear all

NCT03126630 2026-04-01

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

Phase 1/2 Active not recruiting

49 enrolled 20 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant